Find clinical trials in your area

Search by disease and location to discover available clinical trials matching your criteria.

Matched clinical trials

  • Study of LN-144 and LN-145 (Tumor Infiltrating Lymphocytes) in patients with solid tumors, including melanoma, head and neck cancer, and non-small cell lung cancer

    Not recruiting

    2 1 1 1
    Germany Greece Spain
  • Study of Immunotherapy Combinations with GSK4428859, Dostarlimab, and GSK6097608 for Patients with Advanced Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Belgium Finland France Germany Greece Hungary +5
  • Study on the Effectiveness of Retifanlimab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Bulgaria Czechia
  • Study on the Effectiveness and Safety of Alectinib, Entrectinib, and a Drug Combination for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

    Not recruiting

    4 1 1 1
    Investigated diseases:
    Belgium France Germany Italy Poland Spain
  • Study of Amivantamab and Lazertinib Combination vs. Osimertinib vs. Lazertinib for First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated diseases:
    Belgium France Germany Hungary Italy The Netherlands +3
  • Study on Continued Ceritinib Treatment for Patients with ALK Positive Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria France Germany Italy Poland
  • Study of Davutamig (REGN5093) for Patients with Advanced Non-Small Cell Lung Cancer with MET Alterations

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France
  • Study of Nivolumab and Relatlimab for Patients with Resectable Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Germany The Netherlands
  • Study Comparing Lorlatinib and Crizotinib for Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Czechia France Germany Italy The Netherlands +2
  • Study on the Effectiveness and Safety of Osimertinib for Patients with Stage IB-IIIA Non-Small Cell Lung Cancer After Tumor Removal

    Not recruiting

    3 1 1
    Investigated drugs:
    Belgium France Germany Italy Poland Spain +1